Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A. Palma, Robert Olson, Stephen Harrow et al. · Journal of Clinical Oncology · 2020
Abstract Purpose The oligometastatic paradigm hypothesizes that patients with a limited number of metastases may achieve long-term disease control, or even cure, if all sites of disease can be ablated. However, long-term randomized data testing this paradigm are lacking. Methods We enrolled patients with a controlled primary malignancy and 1-5 metastatic lesions, with all metastases amenable to stereotactic ablative radiotherapy (SABR). We stratified by the number of metastases (1-3 vs. 4-5) and randomized in a 1:2 ratio between palliative standard of care (SOC) treatments (Arm 1) vs. SOC plus SABR (Arm 2). We employed a randomized phase II screening design with a primary endpoint of overall survival (OS), using an alpha of 0.20 (wherein a p-value <0.20 indicates a positive trial). Secondary endpoints included progression-free survival (PFS), toxicity, and quality of life (QOL). Herein we present long-term outcomes from the trial. Results Between 2012 and 2016, 99 patients were randomized (33 in Arm 1, 66 in Arm 2) at 10 centres internationally. Median age was 68 (range 43-89) and the majority (n=59; 60%) were male. The most common primary tumor types were breast (n=18), lung (n=18), colorectal (n=18), and prostate (n=16). Median follow-up was 51 months. Five-year OS was 17.7% in Arm 1 (95% confidence interval [CI]: 6-34%) vs. 42.3% in Arm 2 (95% CI: 28-56%; stratified log-rank p=0.006). Five-year PFS was ‘not reached’ in Arm 1 (3.2% [95% CI: 0-14%] at 4-years with last patient censored) and was 17.3% (95% CI: 8-30%) in Arm 2 (p=0.001). There were no new grade 2-5 adverse events and no differences in QOL between arms. Conclusions With extended follow-up, the impact of SABR on OS was larger in magnitude than in the initial analysis, and durable over time. There were no new safety signals, and SABR had no detrimental impact on QOL. ( NCT01446744 ) Funding Ontario Institute for Cancer Research and London Regional Cancer Program Catalyst Grant
Cited by 1,300 works. doi:10.1200/jco.20.00818
Authors
- David A. Palma
- Robert Olson
- Stephen Harrow
- Stewart Gaede
- Alexander V. Louie
- Cornelis J.A. Haasbeek
- Liam A. Mulroy
- Michael I. Lock
- George Rodrigues
- Brian Yaremko
- Devin Schellenberg
- Belal Ahmad
- Sashendra Senthi
- Anand Swaminath
- Neil Kopek
- Mitchell Liu
- Karen Moore
- Suzanne Currie
- Roel Schlijper
- Glenn S. Bauman
References
- Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases
- Tumor Metastasis: Molecular Insights and Evolving Paradigms
- Adenocarcinoma of the Kidney with Metastasis to the Lung: Cured by Nephrectomy and Lobectomy
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
- Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial
- Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
- Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
- Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer
- Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials